Evidence map›Paper›PMID 34642219›Full record

ArticleBMJ case reports2021

Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) with concomitant acute chikungunya virus infection: possible role of new viral trigger.

Abheek Sil, Moni Sankar Bhattacharjee, Atanu Chandra, Jayasri Das Pramanik

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Development and Application of Treatment for Chikungunya Fever.Research and reports in tropical medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Abheek SilDermatology, Venereology, Leprosy, RG Kar Medical College and Hospital, Kolkata, West Bengal, India.ORCID http://orcid.org/0000-0002-8043-2721
Moni Sankar BhattacharjeeInternal Medicine, RG Kar Medical College and Hospital, Kolkata, West Bengal, India.
Atanu ChandraInternal Medicine, RG Kar Medical College and Hospital, Kolkata, West Bengal, India chandraatanu123@gmail.com.ORCID http://orcid.org/0000-0002-3809-8926
Jayasri Das PramanikDermatology, Venereology, Leprosy, RG Kar Medical College and Hospital, Kolkata, West Bengal, India.
R. G. Kar Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) is designated as a potentially lethal adverse drug effect with characteristic signs and symptoms such as skin rash, fever, leucocytosis with eosinophilia or atypical lymphocytes, lymphadenopathy and liver or renal dysfunction. In addition to most commonly implicated drug category (aromatic anticonvulsants), lamotrigine, sulfonamides, dapsone and abacavir may also induce this syndrome. We describe here a case a sulfasalazine-induced DRESS with coexisting chikungunya fever. The shared presentation of fever with rash in both conditions made it a challenging diagnosis. Sulfasalazine hypersensitivity manifesting as DRESS has rarely been reported. Furthermore, we document chikungunya virus (CV) as a possible triggering agent for DRESS. To the best of our knowledge, CV as a viral aetiology in DRESS has not been reported previously in the literature.

Indexed as

Chikungunya FeverDrug Hypersensitivity SyndromeEosinophiliaExanthemaHumansSulfasalazineSulfasalazinedermatologydrugs and medicinestropical medicine (infectious disease)unwanted effects / adverse reactions

Identifiers

PMID34642219
PMCPMC8513226
OpenAlexW3205786619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.